BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 33569786)

  • 1. CD8
    Wang M; Wang B; Fang W
    J Clin Pharm Ther; 2021 Jun; 46(3):832-837. PubMed ID: 33569786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.
    Liu Y; Guo X; Zhan L; Wang L; Wang X; Jiang M
    Comput Math Methods Med; 2021; 2021():4468140. PubMed ID: 34422089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma.
    Ji H; Niu X; Yin L; Wang Y; Huang L; Xuan Q; Li L; Zhang H; Li J; Yang Y; An W; Zhang Q
    Cell Physiol Biochem; 2018; 45(3):951-961. PubMed ID: 29428948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
    Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
    Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited impact of the thymus on immunological recovery during and after chemotherapy in patients with diffuse large B-cell lymphoma.
    Vedel SJ; Tholstrup D; Kolte L; Gaardbo J; Ryder LP; Ersbøll A; Albrecht-Beste E; Jurlander J; Nielsen JO; Nielsen SD
    Scand J Immunol; 2009 Jun; 69(6):547-54. PubMed ID: 19439016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.
    Ansell SM; Stenson M; Habermann TM; Jelinek DF; Witzig TE
    J Clin Oncol; 2001 Feb; 19(3):720-6. PubMed ID: 11157023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy.
    Hou H; Luo Y; Tang G; Zhang B; Ouyang R; Wang T; Huang M; Wu S; Li D; Wang F
    Cancer Cell Int; 2021 May; 21(1):282. PubMed ID: 34044841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCR5
    Tang J; Zha J; Guo X; Shi P; Xu B
    Int Immunopharmacol; 2017 Sep; 50():146-151. PubMed ID: 28662433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
    Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T cell-mediated cytotoxicity is associated with MHC class II expression on malignant CD19+ B cells in diffuse large B cell lymphoma.
    Zhou Y; Zha J; Lin Z; Fang Z; Zeng H; Zhao J; Luo Y; Li Z; Xu B
    Exp Cell Res; 2018 Jan; 362(2):287-292. PubMed ID: 29174982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Morishima S; Nakamura S; Yamamoto K; Miyauchi H; Kagami Y; Kinoshita T; Onoda H; Yatabe Y; Ito M; Miyamura K; Nagai H; Moritani S; Sugiura I; Tsushita K; Mihara H; Ohbayashi K; Iba S; Emi N; Okamoto M; Iwata S; Kimura H; Kuzushima K; Morishima Y
    Leuk Lymphoma; 2015 Apr; 56(4):1072-8. PubMed ID: 24975317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
    Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
    Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel risk stratification of de novo diffuse large B cell lymphoma based on tumour-infiltrating T lymphocytes evaluated by flow cytometry.
    Chen Z; Deng X; Ye Y; Gao L; Zhang W; Liu W; Zhao S
    Ann Hematol; 2019 Feb; 98(2):391-399. PubMed ID: 30377764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis.
    Rozental A; Gafter-Gvili A; Vidal L; Raanani P; Gurion R
    Hematol Oncol; 2019 Feb; 37(1):27-34. PubMed ID: 30216478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
    Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
    Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
    Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
    Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.